胃不全麻痺治療薬市場：薬剤クラス別、適応症別、販売チャネル別-2025-2030年の世界予測

胃不全麻痺治療薬市場は、2023年に43億7,000万米ドルと評価され、2024年には45億4,000万米ドルに達すると予測され、CAGR 6.61％で成長し、2030年には68億5,000万米ドルに達すると予測されています。

胃不全麻痺治療薬は、胃排出遅延に伴う症状を管理する上で極めて重要であり、患者のQOLに大きな影響を与える病態を対象としています。これらの薬剤の市場には、吐き気、嘔吐、胃運動不全を緩和することを目的としたプロキネティクス、制吐剤、その他の新規製剤を含む、さまざまな医薬品ソリューションが含まれます。これらの薬剤の必要性は、胃不全麻痺の一因となる糖尿病やその他の全身性疾患の有病率の増加に起因しており、臨床と在宅ケアの両方の場面で需要を牽引しています。適用範囲は病院、専門クリニック、長期療養施設に及び、エンドユーザーは主に医療従事者や慢性管理が必要な患者です。市場成長に影響を与える主な要因としては、老人人口の拡大、胃不全麻痺に対する意識の高まり、ドラッグデリバリーシステムの進歩などが挙げられます。最近の潜在的なビジネスチャンスは、個別化医療のアプローチに焦点を当て、デジタルヘルス技術を活用して患者のアドヒアランスと転帰を向上させることで活用できます。企業は、革新的な薬剤製剤の研究開発に投資し、統合ケアソリューションのためにヘルスケアプロバイダーとの戦略的パートナーシップを構築することで、こうした機会を活用することができます。しかし、市場は厳しい規制要件、既存薬の潜在的な副作用、効果的な治療に対する高いアンメットニーズなどの課題に直面しています。胃不全麻痺の診断や病因の解明には限界があり、効果的な薬剤開発はさらに複雑になっています。イノベーションは、遺伝子研究やグレリン作動薬や神経調節法のような新規治療ターゲットの探索など、これらのギャップに対処することを優先すべきです。また、栄養補助食品のような代替治療を含めた製品ポートフォリオの多様化や、予測診断や患者に合わせた管理のための人工知能の導入も、事業の成長を支える可能性があります。胃不全麻痺治療薬市場は大きな成長の可能性を秘めているが、その複雑性を克服するには、技術革新と患者中心のソリューションの両方に戦略的に焦点を当て、現在の課題に包括的に対処する必要があります。

市場力学：急速に進化する胃不全麻痺治療薬市場の主要市場インサイトを公開

胃不全麻痺治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の糖尿病人口の増加
  • 医療アクセス向上のためのヘルスケアインフラへの投資増加
• 市場抑制要因
  • 高脂血症治療薬の製剤に使用される原材料の高コスト
• 市場機会
  • 新薬開発のための継続的な研究開発活動
  • 世界の規制当局による医薬品承認の増加
• 市場の課題
  • 胃不全麻痺治療薬の摂取に伴う重篤な副作用

ポーターのファイブフォース：胃不全麻痺治療薬市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、胃不全麻痺治療薬市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：胃不全麻痺治療薬市場における外部からの影響の把握

外部マクロ環境要因は、胃不全麻痺治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析胃不全麻痺治療薬市場における競合情勢の把握

胃不全麻痺治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス胃不全麻痺治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、胃不全麻痺治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨胃不全麻痺治療薬市場における成功への道筋を描く

胃不全麻痺治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大の可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で糖尿病患者数が増加
    • ヘルスケアへのアクセス性を高めるためのヘルスケアインフラへの投資増加
  • 抑制要因
    • 高脂血症治療薬の配合に使用される原材料の高コスト
  • 機会
    • 新薬開発に向けた継続的な研究開発活動
    • 世界中の規制当局による医薬品の承認の増加
  • 課題
    • 胃不全麻痺治療薬の摂取に伴う重篤な副作用
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 胃不全麻痺治療薬市場薬剤クラス別

• 制吐剤
• ボツリヌス毒素注射
• 消化管運動促進剤

第7章 胃不全麻痺治療薬市場適応症別

• 糖尿病性胃不全麻痺
• 特発性胃不全麻痺
• 術後胃不全麻痺

第8章 胃不全麻痺治療薬市場：販売チャネル別

• オフライン
  • 病院薬局
  • 小売薬局
• オンライン

第9章 南北アメリカの胃不全麻痺治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の胃不全麻痺治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの胃不全麻痺治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• AbbVie Inc.
• Amneal Pharmaceuticals, Inc.
• ANI Pharmaceuticals, Inc.
• AstraZeneca PLC
• Atlantic Healthcare PLC
• Bausch Health Companies Inc.
• Bristol-Myers Squibb Company
• Cadila Pharmaceuticals Limited
• Cairn Diagnostics
• Evoke Pharma, Inc.
• GlaxoSmithKline PLC
• Johnson & Johnson Services, Inc.
• Kyowa Kirin International plc
• Lupin Limited
• Medtronic PLC
• Neurogastrx, Inc.
• Novartis AG
• Pfizer, Inc.
• Processa Pharmaceuticals, Inc.
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited
• Theravance Biopharma
• Vanda Pharmaceuticals Inc.
• Viatris Inc.

LIST OF FIGURES

• FIGURE 1. GASTROPARESIS DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. GASTROPARESIS DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. GASTROPARESIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. GASTROPARESIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. GASTROPARESIS DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. GASTROPARESIS DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ANTI-EMETIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY BOTULINUM TOXIN INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY PROKINETIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DIABETIC GASTROPARESIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY IDIOPATHIC GASTROPARESIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY POST-SURGICAL GASTROPARESIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 34. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 35. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 36. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 37. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 38. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 47. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 52. AUSTRALIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 56. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 57. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 58. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 59. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 60. INDIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 61. INDIA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 62. INDIA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 63. INDIA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 64. INDONESIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 65. INDONESIA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 68. JAPAN GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 69. JAPAN GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 72. MALAYSIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 73. MALAYSIA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 76. PHILIPPINES GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 77. PHILIPPINES GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 80. SINGAPORE GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 81. SINGAPORE GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 84. SOUTH KOREA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH KOREA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 88. TAIWAN GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 89. TAIWAN GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 92. THAILAND GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 93. THAILAND GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 96. VIETNAM GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 97. VIETNAM GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 100. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 105. DENMARK GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 106. DENMARK GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 109. EGYPT GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 110. EGYPT GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 113. FINLAND GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 114. FINLAND GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 117. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 118. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 121. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 122. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 125. ISRAEL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 126. ISRAEL GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 129. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 130. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 131. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 132. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 133. NETHERLANDS GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 134. NETHERLANDS GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 137. NIGERIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 138. NIGERIA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 141. NORWAY GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 142. NORWAY GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 145. POLAND GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 146. POLAND GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 147. POLAND GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 148. POLAND GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 149. QATAR GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 150. QATAR GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 151. QATAR GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 152. QATAR GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 153. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 154. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 157. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 158. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 161. SOUTH AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 162. SOUTH AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 165. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 166. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 169. SWEDEN GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 170. SWEDEN GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 173. SWITZERLAND GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 174. SWITZERLAND GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 177. TURKEY GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 178. TURKEY GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 181. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 182. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 185. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 186. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 189. GASTROPARESIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 190. GASTROPARESIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Gastroparesis Drugs Market was valued at USD 4.37 billion in 2023, expected to reach USD 4.54 billion in 2024, and is projected to grow at a CAGR of 6.61%, to USD 6.85 billion by 2030.

Gastroparesis drugs are pivotal in managing symptoms associated with delayed gastric emptying, targeting a condition that significantly affects patients' quality of life. The market for these drugs encompasses a range of pharmaceutical solutions, including prokinetics, antiemetics, and other novel formulations aimed at alleviating nausea, vomiting, and gastric motility deficiencies. The necessity for these drugs arises from the increasing prevalence of diabetes and other systemic diseases, which contribute to gastroparesis, driving demand in both clinical and home-care settings. Application scope extends to hospitals, specialty clinics, and long-term care facilities, while end users primarily include healthcare professionals and patients requiring chronic management. Key factors influencing market growth include the expanding geriatric population, heightened awareness about gastroparesis, and advances in drug delivery systems. Recent potential opportunities could be harnessed by focusing on personalized medicine approaches and leveraging digital health technologies to enhance patient adherence and outcomes. Companies can capitalize on these opportunities by investing in R&D for innovative drug formulations and developing strategic partnerships with healthcare providers for integrated care solutions. However, the market faces challenges, such as stringent regulatory requirements, potential side effects of existing drugs, and a high unmet need for effective treatments. Limitations in diagnosis and understanding of gastroparesis etiology further complicate effective drug development. Innovation should prioritize addressing these gaps, such as through genetic research and exploring novel therapeutic targets like ghrelin agonists or neuromodulation methods. Business growth could also be supported by diversifying product portfolios to include alternative treatments like dietary supplements or incorporating artificial intelligence for predictive diagnostics and tailored patient management. While the gastroparesis drug market exhibits substantial growth potential, navigating its complexities requires a strategic focus on both technological innovation and patient-centered solutions to address current challenges comprehensively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Gastroparesis Drugs Market

The Gastroparesis Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increase in diabetic population across the globe
  • Rising investment in healthcare infrastructure to enhance healthcare accessibility
• Market Restraints
  • High cost of raw materials used in formulation of hyperlipidemia drugs
• Market Opportunities
  • Continuous research & development activities for new drug development
  • Increasing drug approvals by the regulatory authorities worldwide
• Market Challenges
  • Severe side effects associated with the consumption of gastroparesis drugs

Porter's Five Forces: A Strategic Tool for Navigating the Gastroparesis Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Gastroparesis Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Gastroparesis Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Gastroparesis Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Gastroparesis Drugs Market

A detailed market share analysis in the Gastroparesis Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Gastroparesis Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Gastroparesis Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Gastroparesis Drugs Market

A strategic analysis of the Gastroparesis Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Gastroparesis Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amneal Pharmaceuticals, Inc., ANI Pharmaceuticals, Inc., AstraZeneca PLC, Atlantic Healthcare PLC, Bausch Health Companies Inc., Bristol-Myers Squibb Company, Cadila Pharmaceuticals Limited, Cairn Diagnostics, Evoke Pharma, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Kyowa Kirin International plc, Lupin Limited, Medtronic PLC, Neurogastrx, Inc., Novartis AG, Pfizer, Inc., Processa Pharmaceuticals, Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Theravance Biopharma, Vanda Pharmaceuticals Inc., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Gastroparesis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Class, market is studied across Anti-Emetic Agents, Botulinum Toxin Injections, and Prokinetic Agents.
• Based on Indication, market is studied across Diabetic Gastroparesis, Idiopathic Gastroparesis, and Post-surgical Gastroparesis.
• Based on Sales Channel, market is studied across Offline and Online. The Offline is further studied across Hospitals Pharmacies and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increase in diabetic population across the globe
    • 5.1.1.2. Rising investment in healthcare infrastructure to enhance healthcare accessibility
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of raw materials used in formulation of hyperlipidemia drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Continuous research & development activities for new drug development
    • 5.1.3.2. Increasing drug approvals by the regulatory authorities worldwide
  • 5.1.4. Challenges
    • 5.1.4.1. Severe side effects associated with the consumption of gastroparesis drugs
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Gastroparesis Drugs Market, by Drug Class

• 6.1. Introduction
• 6.2. Anti-Emetic Agents
• 6.3. Botulinum Toxin Injections
• 6.4. Prokinetic Agents

7. Gastroparesis Drugs Market, by Indication

• 7.1. Introduction
• 7.2. Diabetic Gastroparesis
• 7.3. Idiopathic Gastroparesis
• 7.4. Post-surgical Gastroparesis

8. Gastroparesis Drugs Market, by Sales Channel

• 8.1. Introduction
• 8.2. Offline
  • 8.2.1. Hospitals Pharmacies
  • 8.2.2. Retail Pharmacies
• 8.3. Online

9. Americas Gastroparesis Drugs Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Gastroparesis Drugs Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Gastroparesis Drugs Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. AbbVie Inc.
• 3. Amneal Pharmaceuticals, Inc.
• 4. ANI Pharmaceuticals, Inc.
• 5. AstraZeneca PLC
• 6. Atlantic Healthcare PLC
• 7. Bausch Health Companies Inc.
• 8. Bristol-Myers Squibb Company
• 9. Cadila Pharmaceuticals Limited
• 10. Cairn Diagnostics
• 11. Evoke Pharma, Inc.
• 12. GlaxoSmithKline PLC
• 13. Johnson & Johnson Services, Inc.
• 14. Kyowa Kirin International plc
• 15. Lupin Limited
• 16. Medtronic PLC
• 17. Neurogastrx, Inc.
• 18. Novartis AG
• 19. Pfizer, Inc.
• 20. Processa Pharmaceuticals, Inc.
• 21. Sanofi S.A.
• 22. Takeda Pharmaceutical Company Limited
• 23. Theravance Biopharma
• 24. Vanda Pharmaceuticals Inc.
• 25. Viatris Inc.